# Efficacy and Safety Trial of 12 Weeks of Treatment With Nebulized SUN-101 in Patients With COPD (GOLDEN-4)

> **NCT02347774** · PHASE3 · COMPLETED · sponsor: **Sunovion Respiratory Development Inc.** · enrollment: 641 (actual)

## Conditions studied

- COPD
- Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** SUN-101 50 mcg BID eFlow (CS) nebulizer
- **DRUG:** SUN-101 25 mcg BID eFlow (CS) nebulizer
- **DRUG:** Placebo eFlow (CS) nebulizer

## Key facts

- **NCT ID:** NCT02347774
- **Lead sponsor:** Sunovion Respiratory Development Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02
- **Primary completion:** 2015-12
- **Final completion:** 2015-12
- **Target enrollment:** 641 (ACTUAL)
- **Last updated:** 2018-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02347774

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02347774, "Efficacy and Safety Trial of 12 Weeks of Treatment With Nebulized SUN-101 in Patients With COPD (GOLDEN-4)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02347774. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*